ArticleThe Journal of experimental medicine1993
Pim-1 levels determine the size of early B lymphoid compartments in bone marrow.
Article in The Journal of experimental medicine, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 73 citations in OpenAlex.
- The Role of PIM Kinases in Pediatric Solid Tumors.Cancers · 2022Review
- At the intersection of DNA damage and immune responses.Nature reviews. Immunology · 2019Review
- A review on PIM kinases in tumors.Bioinformation · 2019Article
- Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Oncotarget · 2016Article
- Developmental stage-specific effects of Pim-1 dysregulation on murine bone marrow B cell development.BMC immunology · 2016Article
- Novel molecular mechanism for generating NK-cell fitness and memory.European journal of immunology · 2015Review
- Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.Frontiers in oncology · 2014Review
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.The Journal of experimental medicine · 2013Article
- Hoxa9 and Flt3 signaling synergistically regulate an early checkpoint in lymphopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.Stem cells (Dayton, Ohio) · 2013Article
- Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients.PloS one · 2013Article
- Integrated signaling in developing lymphocytes: the role of DNA damage responses.Cell cycle (Georgetown, Tex.) · 2012Article
- Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.Blood · 2012Article
- RAG-induced DNA double-strand breaks signal through Pim2 to promote pre-B cell survival and limit proliferation.The Journal of experimental medicine · 2012Article
- Lymphocyte development: integration of DNA damage response signaling.Advances in immunology · 2012Review
- For better or for worse: the role of Pim oncogenes in tumorigenesis.Nature reviews. Cancer · 2011Review
- Hoxa9 regulates Flt3 in lymphohematopoietic progenitors.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Why target PIM1 for cancer diagnosis and treatment?Future oncology (London, England) · 2010Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mouse proto-oncogene Pim-1, which encodes two cytoplasmic serine-threonine-specific protein kinases, is frequently activated by proviral insertion in murine leukemia virus-induced hematopoietic tumors. Transgenic mice overexpressing Pim-1 show a low incidence of spontaneous T cell lymphomas, whereas null mutant mice lack an obvious phenotype. We have analyzed the early B lymphoid compartment from both null mutant and E mu-Pim-1 transgenic mice. The level of Pim-1 expression appears to be a determining factor in the ability of these cells to respond to the growth factors interleukin 7 (IL-7) and SF (steel factor). The impaired response in null mutant mice could be rescued by introduction of a functional Pim-1 transgene. Moreover, overexpression of Pim-1 facilitates the derivation of primitive lymphoid cell lines that are dependent on combined stimulation with IL-7 and SF or insulin-like growth factor 1. These results for the first time identify the involvement of Pim-1 in a normal cellular function, as an important regulator of early B lymphopoiesis in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.